6-Methyl-1,2-dihydrospiro[3,1-benzoxazine-4,4'-piperidine]-2-one | 233261-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6-Methyl-1,2-dihydrospiro[3,1-benzoxazine-4,4'-piperidine]-2-one
• 英文别名: 6-methylspiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one
• CAS: 233261-86-4
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.28
• InChiKey: BKGPHKFLFHYDAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• Chemokine receptor anagonists and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20020169155A1

  公开（公告）日：2002-11-14

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用化合物1或其生理上可接受的盐的有效量。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
  申请人：——

  公开号：US20020119973A1

  公开（公告）日：2002-08-29

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 and physiologically acceptable salts thereof. 2

  披露了新颖的化合物以及一种治疗与异常白细胞招募和/或激活相关疾病的方法。该方法包括向需要治疗的主体施用一种有效量的化合物，该化合物由以下结构表示： 1 以及它们的生理可接受的盐。 2
• Chemokine receptor antagonists and methods of use thereof
  申请人：Luly R. Jay

  公开号：US20050070549A1

  公开（公告）日：2005-03-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2004074273A1

  公开（公告）日：2004-09-02

  The present invention relates to pyridine derivatives or formula (I) where A is a 4-, 5- or 6-membered saturated ring; R1, R2 and R3 are organic groups as specified in the application. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.

  本发明涉及吡啶衍生物或式(I)，其中A是4、5或6成员饱和环；R1、R2和R3是所述申请中指定的有机基团。还描述了它们的制备过程、含有它们的制药组合物以及它们在治疗中的应用，特别是在自身免疫性疾病的调节方面的应用。